SCIENCE & EVIDENCE BASE
Where mechanistic science becomes market access
Evidence as an Asset
Built on peer-reviewed evidence. Designed to the standard regulators require.
Every study Medical Ethics initiates is structured around a specific regulatory or policy objective. But it begins with a mechanistic question: does this evidence confirm the analgesic gap, validate the wound depot kinetics, or demonstrate complementary phase coverage in this species and indication context?
Clinical evidence that answers these questions is not just publishable. It is the direct input that unlocks regulatory submissions, guideline inclusion, and licensing value.
3–5 Day
Time to lesion recovery in FMD field trials, compared to significantly longer untreated baselines (Univ. of Sydney, 2019).
80%
Australian wool growers now use Tri-Solfen® for mulesing and routine husbandry procedures.
Pillars of Evidence
Global welfare standards require minimising pain through effective anaesthesia and analgesia combined. The scientific rationale is precise: from the moment of injury, there is an analgesic gap, a period during which nociception is fully active but systemic NSAIDs have not yet reached therapeutic plasma concentrations. No NSAID crosses the anaesthesia threshold. Topical local anaesthesia is the only mechanism that closes this gap at the wound site and at the moment of injury.
This is the clinical foundation of 44 peer-reviewed publications and 25 regulatory clinical studies supporting the Solfen-Tech evidence base.
Antimicrobial stewardship is built into the protocol by design. Cetrimide provides bactericidal protection at the wound site, preventing the secondary infection cascade that would otherwise amplify and prolong the pain cycle beyond the procedural event. This is not a parallel benefit: it is a direct contributor to sustained analgesia.
At the same time, bupivacaine's wound depot mechanism provides ongoing local anaesthesia through tissue diffusion, confirmed by rising plasma concentrations consistent with flip-flop kinetics. Together, these mechanisms deliver pain control that extends well beyond the acute window, without systemic drug loading.
Solfen-Tech and NSAIDs act on different mechanisms across different phases of the pain response. Tri-Solfen closes the acute nociceptive phase via sodium channel blockade. NSAIDs address the systemic inflammatory phase via COX inhibition. Because these mechanisms do not overlap, the combination produces full-spectrum pain control that neither agent achieves alone.
This complementary phase coverage is the clinical basis for documented performance outcomes: faster wound healing, improved weight gain, earlier return to normal behaviour, and reduced mortality across multiple species and procedural contexts.
Fast facts
3–5 days
To full lesion recovery
$6.5–21bn
Annual global economic losses caused by FMD
136
Animals treated (cattle & buffalo)
48hr
To restored eating behaviour
Registered by Laos veterinary authorities following trial
CASE STUDy
Welfare outcomes that drive economic recovery
FMD Treatment: Mekong, Laos
The Global Problem
Foot-and-Mouth Disease (FMD) causes an estimated US$6.5–21 billion in annual global economic losses (FAO/World Bank). Phase-specific ain management of lesions restores productivity and motivates farmer compliance with disease control programmes.
The Trial & Solution
In April 2019, the University of Sydney School of Veterinary Science deployed Tri-Solfen® to treat an FMD outbreak affecting 136 cattle and buffalo across smallholder farms in the Mekong region of Laos. Disease was present in both vaccinated and unvaccinated animals, with moderate to severe ulcerations of oral tissue and interdigital areas of the feet. Animals were distressed and reluctant to move. Tri-Solfen® was sprayed directly onto oral and foot lesions.
The Outcome
Results were described as clinically impressive: animals recovered eating behaviour within two days and showed visible improvement in demeanour and mobility. The Laos veterinary authorities subsequently registered Tri-Solfen® as a treatment spray for FMD outbreaks.
PEER-REVIEWED PUBLICATIONS
Independent scientific validation
44 peer-reviewed publications across cattle, pigs, sheep, and horses, and 25 regulatory clinical studies, including 6 published clinical studies and 2 in preparation. With strong academic partnerships, independent research has been conducted globally in collaboration with the University of Sydney, Murdoch University, CSIRO, the University of Melbourne, the University of Padua, the University of Lisbon, Zaragoza University Spain, and Massey University New Zealand.
POLICY FRAMEWORK ALIGNMENT
Four global frameworks. One solution.
Tri-Solfen® is uniquely positioned to align simultaneously with the four most powerful global policy frameworks shaping animal health and food systems.
Global AMR Reduction Frameworks
WHO, OIE (WOAH), and national AMR strategies prioritise wound care and reduced antibiotic use at procedure sites. Tri-Solfen®’s cetrimide antiseptic component directly addresses post-procedural infection risk — reducing the need for routine antibiotic prophylaxis. This positions Tri-Solfen® as an AMR stewardship platform technology, not just a welfare product.
One Health Strategy
Cross-species welfare improvement, AMR reduction, and responsible medicine use are core One Health objectives. Tri-Solfen® addresses all three simultaneously — a combination no single-indication competitor can match. This alignment enables policy engagement across animal health, human health, and environmental health agencies.
Welfare Legislation Expansion
National and regional welfare legislation is tightening on routine livestock procedures in the EU, UK, and increasingly across Asia and Latin America. Regulatory approval in each jurisdiction converts this legislation into mandatory demand for an approved, practical solution. Medical Ethics is positioned ahead of regulatory expansion rather than responding to it.
Responsible Production Mandates
Retailer, processor, and certification body requirements for documented pain mitigation protocols are growing. Tri-Solfen® protocol documentation is designed to be embedded directly into processor QA systems and veterinary SOPs — creating technical integration that price competition cannot dislodge.
RESEARCH PARTNERSHIPS
University collaboration network
University of Sydney
ARC Linkage Grant collaboration. Multiple peer-reviewed publications across cattle, sheep and pig indications. FMD field trials in South-East Asia. Led by Prof. Peter Windsor, registered specialist veterinary surgeon.
University of Padua (UNIPD)
Extensive safety and efficacy studies for EU and US regulatory submissions — pig castration and tail docking. Critical dossier support for partnership market entries into Europe.
University of Lisbon
Ongoing research into Tri-Solfen® for hoof lesion treatment in dairy cattle — a major welfare and productivity issue affecting millions of cows globally. Supports European market access strategy.